Santec Holdings (TSE: 6777)
santec Holdings Corporation | Komaki, Aichi, Japan | ~350 employees | Founded 1979 | Listed 2001
Santec makes precision optical instruments and components used to test, measure, and build fiber optic networks and photonic systems. Their tunable lasers are the de facto standard for testing every 400G/800G/1.6T optical transceiver that goes into AI data centers. Their OCT technology goes into cataract surgery devices (via Alcon) and semiconductor wafer inspection. Their LCOS spatial light modulators shape laser beams at power levels nobody else can touch.
This is an A+ business at a price that demands perfection. Founder-family owns ~50%, gross margins are 58%, ROIC is 46%, and the balance sheet is a fortress. But the stock has run 6x off its lows, trades at 41x trailing earnings with only 2 analysts covering it, and the free float is just 39%. You want to own this company -- just not necessarily at this price.
Identity
| Item | Detail |
|---|---|
| Full Name | santec Holdings Corporation (formerly Santec Corporation) |
| Ticker | 6777.T (TSE Standard Market) |
| HQ | 5823 Ohkusa Nenjozaka, Komaki, Aichi, Japan 485-0802 |
| Sector | Precision photonics -- optical T&M instruments, components, biophotonics |
| Founded | August 25, 1979 (as Kyodo Shoji Corporation) |
| Name History | Kyodo Shoji (1979) -> Samcom Electronics (1981) -> Santec Corp (1983) -> Santec Holdings (April 2023) |
| IPO | July 24, 2001 (Osaka Stock Exchange JASDAQ) |
| Employees | ~350 consolidated |
| Fiscal Year End | March 31 |
| Shares Outstanding | ~11.76 million |
| Market Cap | ~JPY 253B (~$1.7B) |
| Website | santec.com |
Forbes Asia "200 Best Under A Billion" in both 2024 and 2025 (consecutive years).
Thesis
Santec is the highest-quality business in the Japan photonics/semi group. Full stop. 58% gross margins, 31% operating margins, 46% ROIC, a fortress balance sheet with JPY 10.7B net cash, and a founder family that owns ~50% of the company. Revenue has compounded at ~34% annually over four years by riding the AI data center optical interconnect buildout -- their tunable lasers are essential for testing every 400G/800G/1.6T transceiver that hyperscalers deploy.
The problem is the stock knows all of this. At 41x trailing P/E and 10x book after a 6x rally from its 52-week low, Santec is priced for perfection. The free float is only 39%, two analysts cover it, and institutional ownership is a startling 5%. This is an A+ business at a fair-to-expensive price. The correct move is to own it on pullbacks, not chase it.
Single most important thing that must go right: AI data center optical interconnect capex must continue to grow. Santec's products test the transceivers that make that infrastructure work.
Expected holding period: 12-36 months, with high sensitivity to entry point.
Exit criteria:
- Sell if hyperscaler capex guidance declines or AI infrastructure spending plateaus
- Sell if operating margins fall below 25% for two consecutive quarters
- Sell if forward P/E exceeds 50x without corresponding earnings acceleration
- Trim if RSI exceeds 85 again
- Take partial profits on any 20%+ drawdown from highs
Silicon Photonics / CPO Disruption Risk
The most important long-term risk deserves its own callout. Silicon photonics and co-packaged optics are growing at ~37% CAGR and could reach $20B by 2036. If optical functions move from discrete components to integrated silicon chips, Santec's discrete components face commoditization. But here's the counterargument: someone still needs to test those integrated photonic circuits, and Santec's test instruments become even more necessary. The TSL-570 Type U was specifically designed for testing CPO modules with high coupling losses. Since instruments are 75% of revenue, the net effect is likely positive -- but the components segment (19%) carries real headwind risk.
Business
What they do (plain language): Santec makes precision optical instruments and components used to test, measure, and build fiber optic networks and photonic systems. Their tunable lasers test optical transceivers for data centers. Their OCT technology goes into cataract surgery devices (via Alcon) and semiconductor wafer inspection. Their spatial light modulators shape high-power laser beams for industrial processing.
Segments (FY2025, ended March 2025)
| Segment | Revenue (JPY B) | % | Description |
|---|---|---|---|
| Optical Instruments | 17.95 | 75% | Tunable lasers (TSL series), swept test systems, IL/RL meters, OCT |
| Optical Components | 4.50 | 19% | LCOS spatial light modulators, monitors, attenuators, filters |
| System Solutions | 1.57 | 6% | Domestic system integration |
Instruments is the profit engine. Components is the swing factor -- it cratered during the inventory correction and is now surging back (+67.4% YoY in 9M FY2026, margins expanding from ~13% to ~27%).
Geographic Mix (FY2025)
| Region | Revenue (JPY B) | % |
|---|---|---|
| USA | 8.23 | 34% |
| Japan | 5.87 | 24% |
| China | 4.85 | 20% |
| Others | 5.08 | 21% |
75% of revenue is overseas. US is the largest market, driven by data center demand. China at 20% is both opportunity and geopolitical risk.
Products & Technology
Tunable lasers (core franchise):
- TSL-570 Type H (high power) and Type U (ultra-high, designed for CPO testing with high coupling losses)
- World's first commercial single-mode external cavity tunable laser (1989) — first mover advantage that still holds
- Sub-picometer resolution, C+L band coverage, narrow linewidth
OCT systems:
- Pioneered commercial swept-source OCT (HSL-2000, 2005) — another genuine first
- ARGOS biometer for cataract surgery (Alcon exclusive distributor, 1,200+ units shipped by March 2022)
- Precision Wafer Mapper for semiconductor inspection — expanding into semi metrology
- Quantum OCT demonstrated at Expo 2025 Osaka
LCOS spatial light modulators:
- SLM-300 (200W) — won Ringier Innovation Award 2024
- SLM-310 (1kW) — first LCOS SLM rated for this power level, opens metal 3D printing market
Recent launches (2025-2026):
- TSL-570 Type U for CPO testing
- SLM-310 (1kW class)
- MTF-Narrow 50 GHz filter for 800G coherent transceivers
- SPA-110 extended range swept photonics analyzer
- PICAlign architecture (with Aerotech and SENKO) for co-packaged optics active alignment
Core technology differentiators:
- Proprietary MEMS micro-mirrors for fast wavelength tuning
- LCOS phase-only modulation adapted for high-power industrial use
- Integrated swept-source OCT engine (laser + interferometer)
- MEMS-tunable VCSEL for ultra-high-speed swept sources (400 kHz, 88nm range)
- MTF-FT flat-top tunable filter with 10x better noise rejection than typical
Competitive Position
Santec is one of the top 5 global tunable laser companies alongside Lumentum, Coherent, MACOM, and (formerly) NeoPhotonics. They hold the de facto standard position in swept-source tunable lasers for T&M. What differentiates them:
- Vertical integration — designs MEMS mirrors, laser cavities, and control electronics in-house
- Pure-play focus — unlike Keysight ($5.7B) or Yokogawa ($4.5B), Santec does nothing but photonics
- Pioneer status in SS-OCT and swept-source technology
- Size = agility — 350 people moving faster than large competitors on CPO testing, quantum photonics
The silicon photonics / CPO disruption question is real but nuanced: even as optical functions integrate onto silicon, someone still needs to test those integrated photonic circuits. The TSL-570 Type U was specifically designed for this. Instruments (75% of revenue) benefit from silicon photonics growth; components (19%) face headwind. Net effect likely positive, but worth monitoring.
Growth Drivers
- AI data center optical interconnect — 400G/800G/1.6T transceivers need extensive optical testing. Santec's tunable lasers are essential test instruments. CPO architecture requires even more sophisticated testing.
- Semiconductor OCT metrology — non-destructive wafer inspection, 3D profiling. Semi metrology market growing to ~$12B by 2032 at 6.5% CAGR. Advanced packaging (3D stacking, chiplets) creates new inspection needs.
- Medical OCT expansion — ARGOS/Alcon partnership, SS-OCT expanding from ophthalmology into cardiology.
- New product cycles — SLM-310 (high-power laser processing), MTF-Narrow (800G coherent), quantum instruments (MOGLabs).
- Acquisition flywheel — JGR/OptoTest (2021, fiber test), MOVU (2025, medical OCT), MOGLabs (2025, quantum lasers), KS Photonics (equity investment, multicore fiber).
Management
This is a family-controlled, founder-led company. The Tei/Chong family holds the top three executive positions and ~50% of shares. The naming is confusing — "Tei" is the Japanese reading and "Chong" the Korean reading of the same kanji. Mototaka Tei (CEO) and Wonho Chong are almost certainly the same person; Daikou Tei and Changho Chong are the same person. The family is likely of Korean heritage using both name systems across databases.
Key Executives
| Name | Title | Notes |
|---|---|---|
| Mototaka Tei (= Wonho Chong) | President & CEO | Since Apr 2020 / CEO June 2022. ~Age 62. 9.07% personal stake (~JPY 23B) |
| Daikou Tei, Ph.D. (= Changho Chong) | EVP & CSO / Chairman | 8.43% stake. Ph.D. With company since at least 2001 |
| Masataka Tei, Ph.D. | EVP & CTO | Third family member in top leadership |
| Keiji Isamoto, Ph.D. | SVP & COO | |
| Jonathan Evans, Ph.D. | VP & Chief Global Sales Officer | International sales |
| Peter Chan, Ph.D. | VP & Chief Product Officer | |
| Noboru Uehara, Ph.D. | CEO, Santec AOC | Optical components |
| Atsushi Andy Morosawa | CEO, Santec LIS | Instruments |
| David Heard, Ph.D. | CEO, Santec Europe |
The team is heavily Ph.D.-credentialed (7+ of top 17 hold doctorates) and internationally diverse. The holding company structure (May 2022) places operating subsidiaries under separate CEOs.
Ownership Structure
| Shareholder | % | Notes |
|---|---|---|
| Sadamura Family / Kohwa Co. | 16.65% | Founder-related entity |
| Chronosource KK | 12.47% | Family asset-holding vehicle |
| Wonho Chong (= Mototaka Tei) / Gens Global | 9.07% | CEO |
| Daikou Tei (= Changho Chong) | 8.43% | EVP/CSO/Chairman |
| Chong Family (direct) | 7.11% | Additional family holdings |
| Employee Stock Ownership | 1.81% |
Total insider/founder: ~50%+. Free float: ~39% (4.62M shares). Institutional ownership: 5.18% (remarkably low). Only 2 analysts cover the stock. This is skin in the game at its most extreme — the family's wealth IS the company.
Governance
Structure: Traditional Japanese Audit & Supervisory Board (kansayaku-kai) model — the least reform-oriented governance model under Japanese law. TSE Standard Market (not Prime), meaning lower governance requirements.
Board: 4 internal directors (3 are family) + 3 external audit members (CPA, attorney, Ph.D.). The external members sit on the audit board, not as full voting directors on strategy. This is weak governance by global standards but common for TSE Standard companies.
Flags:
- 3 of 4 internal board seats are family
- No visible succession plan
- Name opacity across databases makes ownership tracking confusing for foreign investors
- Low institutional ownership = limited external governance pressure
Mitigants:
- No dual-class shares, no poison pills — one-share-one-vote
- Family's ~50% stake worth ~JPY 120B+ aligns interests on value creation (though not necessarily capital return)
- Forbes Asia "200 Best Under A Billion" — 2024 and 2025 (consecutive)
Management grade: A-. Exceptional owner-operator alignment, strong technology culture, coherent strategy. Docked only for traditional governance structure and succession opacity.
Financials
Income Statement (JPY millions)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|---|---|
| Revenue | 7,509 | 8,890 | 15,246 | 18,867 | 24,026 | 30,000 |
| Gross Profit | 3,589 | 4,337 | 8,067 | 10,417 | 14,019 | — |
| Operating Income | 1,421 | 1,642 | 3,983 | 5,564 | 7,429 | 9,300 |
| Net Income | 1,106 | 1,656 | 3,001 | 3,851 | 5,067 | 6,400 |
| EPS (JPY) | 94 | 141 | 255 | 327 | 431 | 544 |
| DPS (JPY) | 35 | 40 | 80 | 90 | 210 | 200 |
Revenue tripled from JPY 8.9B (FY2022) to JPY 30B (FY2026E) in four years. Revenue CAGR FY2021-FY2025: ~34%. Q3 FY2026 was a blowout -- JPY 8.47B revenue, OP +74.4% YoY. Jan 30, 2026 upward revision raised full-year to JPY 30B revenue / JPY 9.3B OP.
Quarterly Trajectory (JPY millions)
| Quarter | Revenue | Op. Income | Notes |
|---|---|---|---|
| Q1 FY2025 (Jun '24) | 6,306 | 2,045 | |
| Q2 FY2025 (Sep '24) | 5,691 | 1,820 | |
| Q3 FY2025 (Dec '24) | 5,316 | 1,558 | |
| Q4 FY2025 (Mar '25) | 6,713 | 2,006 | |
| Q1 FY2026 (Jun '25) | 6,186 | 2,077 | Soft -- China special demand hangover |
| Q2 FY2026 (Sep '25) | 6,592 | 2,043 | Recovery begins |
| Q3 FY2026 (Dec '25) | 8,470 | 2,717 | Blowout quarter -- Components surge |
| Q4 FY2026E (implied) | ~8,752 | ~2,464 | Needs +30.4% YoY -- ambitious |
The sequential inflection in Q3 is the story. Components recovery drove it.
Segment Performance (9M FY2026 cumulative)
| Segment | Revenue | Op. Profit | YoY | Margin | Trend |
|---|---|---|---|---|---|
| Optical Components | JPY 4,487M | JPY 1,202M | +67.4% | ~26.8% | Strongly accelerating |
| Optical Measurement | JPY 14,822M | JPY 5,392M | ~+11.5% | ~36.4% | Stable/mild growth |
| Other | JPY 1,938M | JPY 242M | ~+45% | -- | Growing |
| Total | JPY 21,248M | JPY 6,836M | +22.7% | 32.2% |
Components segment is the key swing factor. Margins expanded from ~13% to ~27% as inventory destocking ended and data center/coherent optical demand surged. Measurement steady but semiconductor wafer inspection in "adjustment phase" -- potential FY2027 headwind.
Margins (expanding relentlessly)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Gross | 47.8% | 48.8% | 52.9% | 55.2% | 58.4% |
| Operating | 18.9% | 18.5% | 26.1% | 29.5% | 30.9% |
| Net | 14.7% | 18.6% | 19.7% | 20.4% | 21.1% |
Gross margins expanded ~1,000bps over 4 years. Operating margins nearly doubled. Extraordinary operating leverage.
Cash Flow (JPY millions)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating CF | 1,607 | 1,406 | 3,113 | 3,281 | 6,001 |
| CapEx | (318) | (392) | (497) | (384) | (1,733) |
| Free Cash Flow | 1,289 | 1,014 | 2,616 | 2,897 | 4,268 |
FY2025 capex jumped to JPY 1.7B (capacity expansion), but OCF growth more than offset it. FCF conversion (FCF/NI) has been ~80% consistently.
Balance Sheet (JPY millions)
| Metric | FY2023 | FY2024 | FY2025 | Q3 FY2026 |
|---|---|---|---|---|
| Cash | 6,297 | 9,373 | 12,539 | 13,708 |
| Total Debt | 1,121 | 1,970 | 2,717 | 2,979 |
| Net Cash | 5,514 | 7,478 | 9,822 | 10,729 |
| Total Equity | 14,333 | 17,735 | 21,427 | 24,807 |
| Equity Ratio | -- | 68.7% | 72.6% | 69.7% |
| Total Assets | 19,605 | 25,828 | 29,527 | 35,591 |
Fortress balance sheet. Net cash/share ~JPY 912. Debt/equity 0.12x. Current ratio 3.23x. Altman Z-Score 7.13 (safe zone). Interest coverage 590x. This company is not going to blow up.
Returns
| Metric | Value |
|---|---|
| ROE | 25-27% |
| ROIC | 21-46% (source-dependent) |
| ROA | 18.3% |
| WACC (est.) | ~6-7% (beta 0.41-0.72) |
| ROIC-WACC spread | +15% to +39% — creating exceptional value |
Valuation (as of March 2026, ~JPY 19,800-21,500)
| Multiple | Value | Verdict |
|---|---|---|
| P/E (TTM) | 37-46x | Very expensive |
| P/E (NTM) | 36.4x | Expensive |
| EV/EBITDA | 23-25x | Rich |
| EV/Revenue | 8-9x | Very rich |
| P/B | 9-11x | Extreme |
| P/FCF | ~54x | Very expensive |
| PEG | ~3.5x (on 10% fwd growth) | Expensive on growth-adjusted basis |
| Dividend Yield | ~0.6% | Token |
Historical comparison: NTM P/E of 36x vs. estimated 5-year average of ~15x = +143% premium. Partially justified by the genuine business re-rating from sleepy optical components maker to AI infrastructure play, but extreme even accounting for that.
Fair value estimates:
| Source | Fair Value | vs. Price |
|---|---|---|
| Simply Wall St (DCF) | JPY 7,822 | -60% |
| Alpha Spread (blended) | JPY 8,015 | -59% |
| Minkabu consensus | JPY 12,656 | -36% |
| MarketScreener (fwd PE x EPS) | JPY 19,539 | ~Fair |
| Deep-dive estimate (32x FY2027E) | JPY 21,000-22,000 | ~Fair |
| Bull case (AI optical accelerates) | JPY 28,500+ | +32% |
Valuation grade: F. A+ business at an F valuation. Every major model says 36-60% overvalued except the most generous forward estimates. At 36x forward P/E, the stock prices in 20%+ EPS growth for 5 years — but consensus FY2027E implies only ~6% growth. The market is betting consensus is wrong.
Capital Allocation
- Dividends: 6x growth in 5 years (JPY 35 → JPY 210). Target 30% payout. Yield is token at 0.6%.
- Buybacks: None identified. Family's ~50% ownership means buybacks primarily benefit insiders.
- M&A: Coherent bolt-on strategy. All tuck-ins, no transformative bets.
| Date | Target | Strategic Logic |
|---|---|---|
| Oct 2021 | JGR Optics (Canada) | Fiber optic cable assembly testing |
| Oct 2021 | OptoTest Corp (California) | IL/RL testing leader for cable assemblies |
| Apr 2025 | MOVU inc. | Medical OCT consolidation (Changho Chong was CEO) |
| May 2025 | MOG Laboratories (Australia) | Quantum photonics -- tunable diode lasers, wavemeters |
| Equity inv. | KS Photonics (Korea) | Multicore fiber components alliance |
- R&D: Not separately disclosed (likely embedded in SGA at ~26% of revenue). Heavy Ph.D. concentration + partnerships with University of Tokyo, Kyushu, Tohoku, USC.
- CapEx: LTM JPY 1.73B (~6% of revenue). FCF yield modest at ~1.7%.
Catalysts & Risks
Catalysts
- AI optical capex acceleration — every hyperscaler expanding data center interconnect = more transceiver testing = more Santec instruments
- Institutional discovery — at 5% institutional ownership, even modest institutional buying moves this stock dramatically
- Analyst coverage initiation — only 2 analysts. New coverage = visibility
- CPO adoption — TSL-570 Type U and PICAlign architecture position Santec at the heart of next-gen interconnects
- Semiconductor OCT — if wafer inspection using OCT takes off, it opens an entirely new market
- WSS market growth — wavelength selective switch market projected $1.08B (2025) → $1.95B (2030) at 12.5% CAGR
Risks
- Valuation compression (HIGH probability, CATASTROPHIC impact) — P/E reversion from 36x toward historical 15x = stock could fall 50%+. At 20x FY2027E (JPY 575 EPS) = JPY 11,500 (-42%). At 15x = JPY 8,625 (-56%).
- AI capex slowdown (MODERATE) — hyperscalers reduce optical spend → revenue stalls → de-rating
- Competition from larger players (MODERATE) — Keysight ($5.7B), Coherent, Lumentum have massive scale advantages. Chinese competitors emerging in lower-end instruments.
- Customer concentration (MODERATE) — not disclosed, but geographic concentration (34% US, 20% China) suggests possible concentration among major transceiver OEMs
- China risk — 20% revenue exposed to geopolitical tensions, export controls, domestic substitution push
- Key-person / succession (LOW-MODERATE) — three family members in top 3 roles, no visible succession plan
- Liquidity — 4.62M share float, thin daily volume. Exits will be painful in a downturn.
- FX — 75% overseas revenue (USD, CNY) with JPY costs. Strong yen = margin compression.
- Technology obsolescence — if optical testing moves to integrated on-chip solutions, standalone instruments face headwinds. MEMS approach could be superseded by photonic integrated circuit alternatives.
Behavioral Traps (as of March 2026)
Three red flags active: FOMO (stock up 237% in 52 weeks), narrative seduction ("AI photonics infrastructure" is one of the most powerful narratives in markets), recency bias (4 consecutive years of 25%+ revenue growth, but extrapolating at 36x P/E is dangerous). The business is so good it creates a false sense of safety. Great businesses bought at extreme valuations produce poor returns.
Technical Context (March 2026)
RSI ~98 (extreme overbought). Price +138% above 200-day MA. Parabolic advance with no consolidation. Golden cross present but the chart pattern historically resolves with 40-60% corrections. Entry trigger: Wait for RSI below 50 and consolidation above 50-day MA, likely meaning a correction to JPY 12,000-15,000 range.
Decision Log
2026-03-01 — Pre-buy checklist: PASS (wait for pullback)
Verdict: PASS at current prices. Santec is the best business in the 5-stock versus analysis. But it is the single worst buy at current prices. At 36-46x P/E with RSI at 98, every valuation model says 36-60% overvalued. Three behavioral traps active.
Action plan:
- Add to watchlist — this is a stock you WANT to own, just not at this price
- Price alerts: JPY 15,000 (25x NTM PE, research starter) → JPY 12,500 (21x, begin buying 40%) → JPY 10,000 (17x, full position)
- Buy triggers: RSI below 50, price below JPY 15,000, P/E below 25x
- Maximum position: 1-2% (liquidity constraint)
- Monitor FY2026 full-year results (May 2026) — must meet/beat raised guidance (JPY 30B rev, JPY 9.3B OP)
- If FY2027E EPS revised up to JPY 700+, the fair value range shifts higher
Earnings Scorecard (Q3 FY2026, Jan 30 2026)
| Category | Grade | Notes |
|---|---|---|
| Revenue vs guidance | A | +22.7% YoY 9M, tracking well ahead of original JPY 26B guide |
| Profit performance | A | OP +26.1%, margin expanding to 32.2% |
| Segment performance | A- | Components explosive (+67%), Measurement solid, semi wafer weakness minor |
| Margin trajectory | A | 3+ years of steady expansion, FCF conversion excellent |
| Cash flow / balance sheet | A | Net cash, equity ratio ~70%, pristine |
| Guidance | A | Raised meaningfully -- rev JPY 26B -> JPY 30B, management has visibility |
| Shareholder returns | B+ | DPS rising (JPY 140 -> JPY 210); no buybacks despite JPY 10.7B net cash |
| Overall | A | One of the cleanest growth stories on TSE in photonics |
2026-03-10 — Deep dive completed
Confirmed A+ business quality. Best margins (58% gross, 31% operating), best ROIC (21-46%), strongest insider alignment (~50% family) among the four Japan stocks. Approximately fairly valued at JPY 21,530 on ~32x FY2027E earnings of JPY 663. Not a screaming buy, not overvalued either. Best entry on pullback to JPY 16,000-18,000. Revenue growth reaccelerating above 25% YoY for two consecutive quarters would be an add trigger.
2026-03-10 — Management DD completed
Grade: A-. Exceptional owner-operator alignment through direct ~50% ownership. Strong technology culture (7+ Ph.D.s in leadership). Coherent M&A strategy. Docked for: traditional governance structure (kansayaku-kai model), 3 of 4 internal directors being family, no visible succession plan, and naming opacity across databases.
Unverified / Needs Confirmation
- Management naming — "Wonho Chong" (MarketScreener) = "Mototaka Tei" (Santec website) — strongly indicated but not officially confirmed
- R&D spending — not separately disclosed; likely embedded in SGA (JPY 6.35B / ~26% of revenue)
- Specific tunable laser market share — "top 5 globally" is directional but not precisely quantified
- Customer concentration — no names or ratios disclosed
- ROIC methodology — sources range 21-46% depending on calculation method
Sources
- Santec Official Website
- Santec IR / Financial Statements
- Santec Management Team
- Santec Company History
- StockAnalysis - 6777
- Simply Wall St - Santec
- MarketScreener - Santec
- Kabutan - 6777
- Minkabu - 6777
- Omega Investment - Santec
- Alpha Spread - 6777 Valuation
- irbank EDINET filings
- irbank TDNET filings
- Mordor Intelligence - Tunable Laser Market
- Santec - CPO Testing
- The Worldfolio - Santec CEO Interview
Related
- 6777-filings -- chronological earnings and filing history
- santec-vs-jem-vs-anritsu-and-more-versus -- peer comparison (5-stock showdown)
- optical-components-primer -- industry primer covering Santec's full market
- primer-networking-optics -- fiber optics supply chain
- 6754 -- Anritsu, direct competitor in optical T&M
- JP -- Japan semi buy checklist with entry levels
- silicon-photonics-ai-datacenters -- NVIDIA micro-ring modulator strategy (CPO context)
- tsmc-coupe-silicon-photonics -- TSMC COUPE co-packaged optics platform
Topics
- ai-infrastructure
- optical-components
- japan-semi